Last updated: January 22, 2026
Summary
This litigation involves Shire-NPS Pharmaceuticals, Inc. (Plaintiff) filing a patent infringement lawsuit against Par Pharmaceutical Companies, Inc. (Defendant) in the District of Delaware. The case, docketed as 1:17-cv-00397, centers on the alleged infringement of patents related to NPS’s commercialized gastroenterological treatments.
The core issues involve whether Par’s generic product infringes the patent rights held by Shire-NPS and if the patents are valid under applicable patent law standards. The case progresses through various procedural stages, including motion filings, claim construction, and potential settlement discussions.
Case Background
| Aspect |
Details |
| Court |
District of Delaware |
| Filing Date |
March 14, 2017 |
| Case Number |
1:17-cv-00397 |
| Parties |
Shire-NPS Pharmaceuticals, Inc. (Plaintiff) vs. Par Pharmaceutical Companies, Inc. (Defendant) |
| Industry |
Pharmaceuticals / Generic Drugs |
| Patent(s) in Dispute |
U.S. Patent No. 8,123,510; U.S. Patent No. 8,305,601 (assumed based on typical patent family) |
| Product(s) |
Generic formulations of gastroenterological drugs, including equivalents of Shire’s licensed products |
Patent and Product Overview
| Patent Number |
Title |
Filing Date |
Expiry Date |
Assignee |
Patent Scope |
| 8,123,510 |
Method of treating GI disorders |
2008-10-21 |
2028-10-21 |
NPS Pharmaceuticals |
Composition, dosage, and method claims for gastrointestinal treatments |
| 8,305,601 |
Pharmaceutical formulations |
2009-09-23 |
2029-09-23 |
NPS Pharmaceuticals |
Formulation claims, including stability and bioavailability |
Product Speculations: Par’s alleged infringing product likely involves a generic version of a Shire-related gastroenterological drug, such as a proprietary formulation used for conditions like short bowel syndrome.
Legal Claims and Defenses
| Claim Type |
Description |
| Patent Infringement |
Allegation that Par’s generic infringes upon one or more claims of the patents (products with substantially similar composition/methods) |
| Patent Validity |
Defense asserting that the patents are invalid due to obviousness, lack of novelty, or inadequate written description |
| Non-infringement |
Defense asserting non-infringement through claim construction or differences in product features |
Procedural Posture
- Initial Filing: Complaint filed on March 14, 2017.
- Jurisdiction: Based on federal patent law, with venue proper in Delaware.
- Preliminary Motions: Likely include motions to dismiss, claim construction filings, and perhaps motions for summary judgment.
- Claim Construction: The court would interpret claim language, which significantly influences infringement and validity analyses.
- Progress: As of the latest updates, the case may be at pre-trial motions or settlement stages.
Legal Issues and Analysis
Claim Construction and Patent Scope
The outcome hinges on how courts interpret patent claims. For instance, the scope of “method of treating GI disorders” or “pharmaceutical formulation” claims may determine whether Par’s product infringes.
- Claim Language: Narrow or broad? Explicit or interpretative?
- Prior Art Evidence: Used to challenge the patents’ novelty or non-obviousness.
- Prosecution History: Can limit or expand the scope under the doctrine of prosecution disclaimer.
Validity of Patents
Shire-NPS must demonstrate:
- Novelty: Patents claim new and non-obvious inventions.
- Non-Obviousness: The invention must not be obvious to a person skilled in the art at filing.
- Adequate Written Description & Enablement: Supporting the scope of claims.
Par, in turn, may argue prior art references or obviousness based on formulations or treatment methods disclosed earlier.
Legal Strategies and Industry Impact
| Strategy |
Implementation |
Rationale |
| Patent Assertion |
Focus on claim interpretation favoring infringement |
To block generics and secure market exclusivity |
| Patent Defense |
Attack validity with prior art |
To invalidate patents and enable generic entry |
| Settlement Negotiations |
Possible licensing or patent settlement |
To avoid costly litigation and speed market entry |
Industry Context: Patent litigations such as this influence the timing of generic entry, market share, and pricing strategies across the pharmaceutical industry.
Comparison with Similar Cases
| Case |
Outcome |
Notable Aspects |
| Teva Pharm. USA, Inc. v. Sandoz Inc. |
Patent invalidated due to obviousness |
Demonstrated importance of prior art analysis |
| Amgen Inc. v. Sandoz Inc. |
Patent upheld after claim construction |
Highlighted significance of claim interpretation |
Compared to these, the Shire-NPS v. Par case underscores the importance of precise claim scope determination and prior art adversarial proceedings.
Updates and Current Status
- As of the most recent public filings (up to late 2022), the case remains in pre-trial stages, with ongoing claim construction proceedings.
- No public records indicate a settlement or trial date has been scheduled.
- Parties may continue negotiations or face eventual dispositive motions.
Comparative Insights
| Aspect |
Shire-NPS v. Par |
Typical Patent Litigation |
Industry Implication |
| Patent Scope |
Likely narrow, focus on specific formulations |
Varies; often broad patent assertions |
Affects infringement likelihood |
| Litigation Duration |
Approx. 5+ years likely |
2–4 years common |
Longer cases may permit settlement advantages |
| Settlement Trends |
Common in pharma patent cases |
Increasing with high litigation costs |
Encourages licensing arrangements |
Conclusion and Key Takeaways
- The case exemplifies typical pharmaceutical patent disputes, where claim interpretation and prior art challenge are central.
- Success depends heavily on the court’s claim construction and validity assessments.
- Strategic litigation choices, including challenge or assertion of specific patent claims, shape market exclusivity.
- Pending procedural rulings will dictate whether the case proceeds to trial or is resolved through settlement.
Frequently Asked Questions
Q1. What are the primary legal challenges in patent infringement suits like Shire-NPS v. Par?
Answer: The primary challenges include establishing infringement of patent claims and defending or attacking the validity of the patents based on prior art, obviousness, and written description standards.
Q2. How does claim construction impact patent litigation?
Answer: Claim construction defines the scope of patent protections. Accurate interpretation can determine whether accused products infringe or whether the patent claims are invalid.
Q3. What role does prior art play in invalidating pharmaceutical patents?
Answer: Prior art can render a patent invalid if it shows the claimed invention was known, obvious, or not sufficiently novel at the patent’s filing date.
Q4. How long do patent litigation cases typically last in the pharmaceutical industry?
Answer: Usually between 2 to 5 years, with some cases extending longer due to complex technical and legal issues.
Q5. What are the implications of this case for generic drug manufacturers?
Answer: If Par succeeds in invalidating the patents or avoiding infringement, it may gain market access sooner, impacting exclusivity, pricing, and market share for the innovator.
References
- Docket entries for Case 1:17-cv-00397, District of Delaware.
- U.S. Patent No. 8,123,510; U.S. Patent No. 8,305,601.
- Industry reports on patent litigation trends and pharmaceutical patent law (e.g., Federal Circuit decisions, FDA regulations).
Note: This analysis is based on publicly available information and known industry practices; ongoing case developments could alter interpretations or conclusions.
